$612 | SAVE $83 | Single User
$1228 | SAVE $167 | Global License

Physician Views: Do EU pulmonologists anticipate rapid uptake for GSK’s Seretide-successor?
[Published by FirstWord Pharma]

Published by FirstWord Pharma: 01 Jul 2013 | 53 | In Stock
Related Topics: FDA , GlaxoSmithKline , Relvar Ellipta

Introduction

Scope


As GlaxoSmithKline's Relvar Ellipta – a once-daily successor to its multi-billion dollar Seretide franchise – nears expected approval in Europe, this week's FirstWord Physician Views poll will ask pulmonologists based in the 5EU markets (France, Germany, Italy, Spain and the UK) about their usage of twice-daily long-acting beta agonist (LABA)/inhaled corticosteroid (ICS) combination products, how they expect to use a once-daily alternative and their perception of payer attitudes to such a product.


Relvar has already been approved by the FDA and is marketed in the US under the name Breo Ellipta. It has recently been launched and priced comparably to Seretide – a strategy that appears designed to facilitate a more favourable reimbursement status and encourage greater switching of patients from the older twice-daily product.


Physicians in the US appear to need less convincing than payers on the benefits of a once-daily therapy that should boost patient compliance and drive improvements in long-term outcomes. FirstWord Pharma PLUS subscribers can access results from an earlier Physician Views poll of US-based pulmonologist attitudes towards Breo


The attitude of European pulmonologists towards usage of a once-daily LABA/ICS combination therapy could provide an interesting counterpoint to the view of US-based physicians, particularly as GlaxoSmithKline can be expected to face an even more stringent attitude towards reimbursement for Relvar in Europe.


Puchase Reasons


This week's Physician Views poll will specifically ask pulmonologists based in the 5EU countries:


  • What percentage of COPD patients they currently treat with twice-daily (BID) LABA/ICS combination therapies?

  • What percentage of these patients fail to comply with BID dosing?

  • What percentage of patients treated with Seretide they expect to switch to Relvar Ellipta based on its once-daily (QD) dosing profile?

  • Their assessment of the efficacy benefit provided by Relvar Ellipta over Seretide

  • How restrictive they expect payers to act towards Relvar Ellipta given that its QD dosing profile is likely to be perceived as its primary form of differentiation versus Seretide
  • Table of Contents
    for Physician Views: Do EU pulmonologists anticipate rapid uptake for GSK’s Seretide-successor? [Published by FirstWord Pharma]

    Additional Details

    Publisher

    FirstWord Pharma

    Publisher Information

    Reference

    53 |

    Report Format

    PDF

    FirstWord Pharma Reports

    Related Reports

    TitleDate PublishedPrice fromMore Details
    SAVE 12% today! Physician Views: Can the launch of ViiV Healthcare's dolutegravir disrupt Gilead's dominance in the HIV market?
    ScopeBased on current timelines, the FDA is poised to approve the HIV therapy dolutegravir later thi...
    01 Aug 2013 by FirstWord Pharma USD $612 (normally
    USD $695)
    More Info
    SAVE 12% today! Physician Views: Will generic Copaxone have traction in the MS market given emergence of oral therapies?
    ScopeA recent ruling by the US Court of Appeals for the Federal Circuit has increased the likelihood...
    01 Aug 2013 by FirstWord Pharma USD $612 (normally
    USD $695)
    More Info
    SAVE 12% today! Physician Views: Can GlaxoSmithKline strike early with Anoro? / What role will dosing, inhaler type play in uptake of LAMA/LABA combinations for COPD?
    ScopeThis year looks set to be one of notable evolution for the US chronic obstructive pulmonary dis...
    01 Aug 2013 by FirstWord Pharma USD $612 (normally
    USD $695)
    More Info
    SAVE 12% today! Physician Views: Which diabetes company does the best marketing job? What is key for companies launching products?
    ScopeThe importance of marketing is increasingly coming to the fore as diabetes-focused companies ba...
    01 Aug 2013 by FirstWord Pharma USD $612 (normally
    USD $695)
    More Info
    SAVE 12% today! Physician Views: Post ADA view on key diabetes market developments
    ScopeLast week’s American Diabetes Association (ADA) meeting provided further evidence that the diab...
    01 Jul 2013 by FirstWord Pharma USD $612 (normally
    USD $695)
    More Info
    SAVE 12% today! Physician Views: Biosimilar Remicade poised for approval in Europe – are rheumatologists and gastroenterologists ready?
    ScopeThe recent recommendation to approve a biosimilar version of Merck & Co./Johnson & Johnson's Re...
    01 Jul 2013 by FirstWord Pharma USD $612 (normally
    USD $695)
    More Info
    SAVE 12% today! Physician Views: Key developments in the European diabetes market - will endocrinologists embrace Tresiba and Forxiga? – both rejected by the FDA
    ScopeEuropean-based endocrinologists are currently getting to grips with two new products that have ...
    01 Jul 2013 by FirstWord Pharma USD $612 (normally
    USD $695)
    More Info
    SAVE 12% today! Physician Views: Recent developments in US diabetes market – impact of safety concerns & emergence of SGLT-2 drug class
    ScopeWith the diabetes market an important therapeutic area for a host of pharmaceutical manufacture...
    01 Jun 2013 by FirstWord Pharma USD $612 (normally
    USD $695)
    More Info
    SAVE 12% today! Physician Views: Life after Gleevec in the chronic myeloid leukaemia (CML) market?
    ScopeNovartis' Gleevec is widely credited as being one of the most important drug launches of all ti...
    01 Jun 2013 by FirstWord Pharma USD $612 (normally
    USD $695)
    More Info
    SAVE 12% today! Surveying Physician Uptake of Mobile Devices and Apps
    IntroductionThe latest medical application software is increasing physicians’ use of mobile technolo...
    01 Oct 2012 by FirstWord Pharma USD $612 (normally
    USD $695)
    More Info

    This report is published by FirstWord Pharma

    Download Free Report Summary PDF

    Physician Views: Do EU pulmonologists anticipate rapid uptake for GSK’s Seretide-successor? [Published by FirstWord Pharma] | Download PDF Summary

    Download our FREE report summary PDF. It contains all the information on these web pages, plus a Proforma Invoice request form, should you need it to satisfy your company's internal order procedures.

    Ordering Information

    Orders are processed immediately and you will be notified of the despatch date on confirmation of your order.

    Accepted Card Types

    Payment

    Buy now using our secure payment system.

    We Stock...